BioAge Labs, Inc. Common Stock (BIOA) Stock Price

BIOAStock
$4.84−5.28%52W
Market Cap$222.14M
P/E—
PEG Ratio—
Div yield—
Beta2.33

BIOA Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-80.70%
Price vs S&P 500 (4W)-38.85%
VGM Score38.36

BIOA Earnings Surprise History

QuarterReport dateEPS estimateEPS actualSurprise
Q2 2026-$0.62-$0.58+7.09%(+$0.04)
Q1 2026-$0.63-$0.52+17.13%(+$0.11)
Q4 2025-$0.67-$0.72-7.69%(-$0.05)
Q3 2025-$0.51-$0.56-9.02%(-$0.05)
Q2 2025-$0.38-$0.60-57.31%(-$0.22)

BIOA Analyst Recommendations

Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.20
4.20
4.20
4.20

Industry Peers — Pharmaceuticals(574)

SymbolValue ScoreGrowth ScoreMomentum ScoreP/S Ratio (TTM)Revenue Growth TTM (YoY)Gross Margin (TTM)EPS Growth (5Y)Price
BIOABioAge Labs, Inc. Common Stock
CCD21.5x———$4.84
LLYEli Lilly & Co.DBA14.9x49.6%83.4%27.6%$1257.03
JNJJohnson & JohnsonDCB6.2x7.8%67.7%14.9%$255.56
ABBVABBVIE INC.DCA7.8x10.4%72.8%-2.9%$285.42
MRKMerck & Co., Inc.DCA5.4x4.6%77.3%21.2%$145.95
NVSNovartis AGCCB4.9x3.3%75.0%15.3%$150.62
AZNAstraZeneca PLCCBB4.3x8.6%81.3%21.9%$165.41
ABTAbbott LaboratoriesCCB3.9x8.1%56.8%8.2%$104.89
NVONovo-Nordisk A/SBCC3.5x5.6%80.7%20.7%$38.83
PFEPfizer Inc.CDA2.6x-0.2%74.7%-3.5%$29.58
VRTXVertex Pharmaceuticals IncDCB10.1x10.2%86.0%8.3%$499.74

About BioAge Labs, Inc. Common Stock

Bioage Labs is a clinical-stage biopharmaceutical company developing treatments for metabolic diseases like obesity by targeting the biology of aging. Its pipeline includes NLRP3 inhibitors and APJ agonists designed to address the underlying mechanisms of age-related metabolic dysfunction.